Ataluren 250mg granules for oral suspension sachets
NHS hospitals in England used £23,745,096 of indicative cost of Ataluren 250mg granules for oral suspension sachets in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 9.7% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Ataluren 250mg granules for oral suspension sachets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Ataluren 250mg granules for oral suspension sachets most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Cambridge Univ Hosp Nhs Foundation Trust | £2,111,688 |
| Alder Hey Childrens Nhs Foundation Trust | £1,828,104 |
| Sheffield Children's Nhs Ft | £1,635,672 |
| Manchester University Nhs Ft | £1,564,776 |
| Lancashire T/Ing Hsp Nhs Foundation Trus | £1,488,816 |
| Nottingham University Hospitals Trust | £1,397,664 |
| University Hospital Southampton Nhs Ft | £1,367,280 |
| Guy's & St Thomas' Nhs Foundation Trust | £1,271,064 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £1,048,248 |
| University College London Foundation Tr | £1,048,248 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.